Scynexis (NASDAQ:SCYX) is a biotechnology company focused on developing innovative therapies for difficult-to-treat and life-threatening infections. Its operations are grounded in the discovery, development, and commercialization of products that aim to overcome antimicrobial resistance and provide needed solutions in the infectious disease space. One of its flagship projects is the development of ibrexafungerp, a novel antifungal agent that represents a new therapeutic class, aimed at treating a variety of fungal infections. The objective of Scynexis is to address the significant unmet needs in the treatment of fungal infections and to improve the lives of patients facing these challenging diseases. Through its focused approach, Scynexis strives to become a key player in the infectious disease market by bringing forward novel treatments that can impact patient care significantly.